antisense

Wave, with new data, plots path forward for Huntington’s drug
BioPharma Dive
Tue, 06/25/24 - 09:08 pm
Wave Life Sciences
Huntington's disease
antisense
WVE-003
Stoke’s shares shoot up 90% as epilepsy drug slashes convulsive seizures
Fierce Biotech
Tue, 03/26/24 - 11:13 am
Stoke Therapeutics
antisense
seizures
Dravet syndrome
STK-001
FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen
Pharmaphorum
Mon, 02/12/24 - 10:28 am
GSK
FDA
fast track
hepatitis B
bepirovirsen
antisense
Ionis Notches Phase III Win in Rare Genetic Disease, Plans to Submit NDA
BioSpace
Tue, 09/26/23 - 09:54 pm
Ionis Pharmaceuticals
antisense
olezarsen
Roche drops antisense drug after seeing efficacy data, leaving Biogen, Ionis and Ultragenyx to duke it out
Fierce Biotech
Fri, 06/23/23 - 09:46 am
Roche
Angelman Syndrome
antisense
Biogen
Ionis Pharmaceuticals
Ultragenyx
rugonersen
Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target
Fierce Biotech
Tue, 05/23/23 - 11:41 am
Wave Life Sciences
antisense
WVE-004
clinical trials
ALS
dementia
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Fierce Biotech
Wed, 09/7/22 - 10:18 am
AstraZeneca
Ionis Pharmaceuticals
Alnylam
antisense
ATTRv-PN
aplontersen
Hepatitis B: can GSK’s bepirovirsen deliver functional cure?
Clinical Trials Arena
Fri, 07/29/22 - 10:10 am
GSK
bepirovirsen
hepatitis B
antisense
GSK hepatitis B hope bepirovirsen heads for phase 3 test
Pharmaforum
Mon, 06/27/22 - 10:18 am
GSK
hepatitis B
clinical trials
antisense
bepirovirsen
After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect
Fierce Biotech
Fri, 06/3/22 - 09:16 am
Biogen
Ionis Pharmaceuticals
ALS
clinical trials
antisense
SOD1-ALS
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues
Fierce Biotech
Wed, 01/5/22 - 10:32 pm
Ultragenyx
GeneTx Biotherapeutics
Angelman Syndrome
clinical trials
antisense
GTX-102
Biogen brings in a successor to Spinraza
BioPharma Dive
Tue, 01/4/22 - 10:49 pm
Biogen
Ionis Pharmaceuticals
Spinraza
BIIB115
antisense
spinal muscular atrophy
AstraZeneca, Ionis close deal on antisense therapy development
Pharmaceutical Business Review
Thu, 12/30/21 - 11:07 am
AstraZeneca
Ionis Pharmaceuticals
antisense
eplontersen
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet
Fierce Biotech
Wed, 11/24/21 - 10:15 am
Pfizer
Regeneron
antisense
clinical trials
vupanorsen
dyslipidemia
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
Endpoints
Thu, 09/9/21 - 11:01 am
Ionis Pharmaceuticals
antisense
Flamingo Therapeutics
RNA
Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial
Fierce Biotech
Wed, 08/25/21 - 11:15 am
Cardior
antisense
heart failure
Bristol Myers Squibb
funding
Ultragenyx pauses antisense trial after patients lose ability to walk
Fierce Biotech
Tue, 10/27/20 - 10:40 am
Ultragenyx
clinical trials
GTX-102
antisense
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2
Pharmaforum
Fri, 08/28/20 - 10:36 am
GSK
antisense
hepatitis B
clinical trials
GSK3228836
Ionis Pharmaceuticals
Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into pivotals
Endpoints
Wed, 01/22/20 - 11:00 am
Novartis
Akcea
Medco
AKCEA-APOCIII-LRx
antisense
GSK licenses Ionis' midphase hepatitis B program for $25M
Fierce Biotech
Tue, 08/27/19 - 09:51 am
GSK
Ionis Pharmaceuticals
antisense
hepatitis B

Pages